Differential behavioral reinforcement effects of dopamine receptor agonists in the rat with bilateral lesion of the posterior ventral tegmental area

Behavioural Brain Research

Volumn 252, Issue , 2013, Pages 24-31

  Ouachikh, Omar ^a   Dieb, Wisam ^a   Durif, Franck ^a,b   Hafidi, Aziz ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

6 OHDA; Conditioned place preference; Parkinson; Reward

Indexed keywords

3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; BROMOCRIPTINE; COCAINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; PRAMIPEXOLE;

ADDICTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; MALE; MOTIVATION; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REINFORCEMENT; SENSITIZATION; VENTRAL TEGMENTUM;

6-OHDA; CONDITIONED PLACE PREFERENCE; PARKINSON; REWARD;

ADRENERGIC AGENTS; ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; BRAIN; COCAINE; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; GAIT DISORDERS, NEUROLOGIC; MALE; MOTIVATION; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; REINFORCEMENT (PSYCHOLOGY); TIME FACTORS; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA;

EID: 84879385569     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.05.042     Document Type: Article

References (85)

1. Abrahams B.S., Rutherford J.D., Mallet P.E., Beninger R.J. Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434. European Journal of Pharmacology 1998, 343:111-118.
2. Anzalone A., Lizardi-Ortiz J.E., Ramos M., De Mei C., Hopf F.W., Iaccarino C., et al. Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors. Journal of Neuroscience 2012, 32:9023-9034.
3. Ashby C.R., Paul M., Gardner E.L., Heidbreder C.A., Hagan J.J. Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse 2003, 48:154-156.
4. Aujla H., Beninger R.J. The dopamine D(3) receptor-preferring partial agonist BP 897 dose-dependently attenuates the expression of amphetamine-conditioned place preference in rats. Behavioural Pharmacology 2005, 16:181-186.
5. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. Journal of Neurological Sciences 1973, 20:415-455.
6. Biondo A.M., Clements R.L., Hayes D.J., Eshpeter B., Greenshaw A.J. NMDA or AMPA/kainate receptor blockade prevents acquisition of conditioned place preference induced by D(2/3) dopamine receptor stimulation in rats. Psychopharmacology (Berl) 2005, 179:189-197.
7. Blanchet P.J., Grondin R., Bédard P.J., Shiosaki K., Britton D.R. Dopamine D1 receptor desensitization profile in MPTP-lesioned primates. European Journal of Pharmacology 1996, 309:13-20.
8. Blunt S.B., Jenner P., Marsden C.D. Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment with l-dopa and carbidopa. Brain Research 1992, 582:299-311.
9. Bordet R. Central dopamine receptors: general considerations (Part 1)]. Revista de Neurologia (Paris) 2004, 160:862-870.
10. Bouthenet M.L., Souil E., Martres M.P., Sokoloff P., Giros B., Schwartz J.C. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Research 1991, 564(November):203-219.
11. Carr D.B., Sesack S.R. Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. Journal of Neuroscience 2000, 20:3864-3873.
12. Cervo L., Silvia Burbassi Colovic M., Caccia S. Selective antagonist at D3 receptors, but not non-selective partial agonists, influences the expression of cocaine-induced conditioned place preference in free-feeding rats. Pharmacology Biochemistry and Behavior 2005, 82:727-734.
13. Chaperon F., Thiébot M.H. Effects of dopaminergic D3-receptor-preferring ligands on the acquisition of place conditioning in rats. Behavioural Pharmacology 1996, 7:105-109.
14. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science 1977, 197:596-598.
15. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122:1437-1448.
16. David H.N., Ansseau M., Abraini J.H. Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of intact animals. Brain Research Brain Research Reviews 2005, 50:336-360.
17. De.Keyser J., De Backer J.P., Wilczak N., Herroelen L. Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum. Progress in Neuropsychopharmacology & Biological Psychiatry 1995, 19:1147-1154.
18. Diaz J., Pilon C., Le Foll B., Gros C., Triller A., Schwartz J.C., et al. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. Journal of Neuroscience 2000, 20:8677-8684.
19. Duarte C., Lefebvre C., Chaperon F., Hamon M., Thiébot M.H. Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats. Neuropsychopharmacology 2003, 28:1903-1915.
20. Evans A.H., Strafella A.P., Weintraub D., Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Movement Disorders 2009, 24:1561-1570.
21. Fenu S., Wardas J., Morelli M. Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease. Behavioural Pharmacology 2009, 20:363-379.
22. Francès H., Smirnova M., Leriche L., Sokoloff P. Dopamine D3 receptor ligands modulate the acquisition of morphine-conditioned place preference. Psychopharmacology (Berl) 2004, 175:127-133.
23. Gagnon C., Bedard P.J., Rioux L., Gaudin D., Martinoli M.G., Pelletier G., et al. Regional changes of striatal dopamine receptors following denervation by 6-hydroxydopamine and fetal mesencephalic grafts in the rat. Brain Research 1991, 558:251-263.
24. Graham D.L., Hoppenot R., Hendryx A., Self D.W. Differential ability of D1 and D2 dopamine receptor agonists to induce and modulate expression and reinstatement of cocaine place preference in rats. Psychopharmacology 2007, 191:719-730.
25. Guillin O., Griffon N., Diaz J., Le Foll B., Bezard E., Gross C., et al. Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway. International Review of Neurobiology 2004, 59:425-444.
26. Gyertyán I., Gál K. Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference. Neuroreport 2003, 14:93-98.
27. Hametner E.M., Seppi K., Poewe W. Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. Clinical Interventions in Aging 2012, 7:83-88.
28. Heidbreder C.A., Gardner E.L., Xi Z.X., Thanos P.K., Mugnaini M., Hagan J.J., et al. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Research Brain Research Reviews 2005, 49:77-105.
29. Heidbreder C.A., Newman A.H. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Annals of the New York Academy of Sciences 2010, 1187:4-34.
30. Hoffman D.C., Dickson P.R., Beninger R.J. The dopamine D2 receptor agonists, quinpirole and bromocriptine produce conditioned place preferences. Progress in Neuropsychopharmacology & Biological Psychiatry 1988, 12:315-322.
31. Hoffman D.C., Beninger R.J. Selective D1 and D2 dopamine agonists produce opposing effects in place conditioning but not in conditioned taste aversion learning. Pharmacology Biochemistry and Behavior 1988, 31:1-8.
32. Huston J.P., Silva M.A., Topic B., Müller C.P. What's conditioned in conditioned place preference?. Trends in Pharmacological Sciences 2013, 34:162-166.
33. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Research Reviews 2007, 56:27-78.
34. Ito R., Robbins T.W., Everitt B.J. Differential control over cocaine-seeking behavior by nucleus accumbens core and shell. Nature Neuroscience 2004, 7:389-397.
35. Jankovic J., Poewe W. Therapies in Parkinson's disease. Current Opinion in Neurology 2012, 25:433-447.
36. Kaasinen V., Ruottinen H.M., Någren K., Lehikoinen P., Oikonen V., Rinne J.O. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. Journal of Nuclear Medicine 2000, 41:65-70.
37. Kauer J.A., Malenka R.C. Synaptic plasticity and addiction. Nature Reviews Neuroscience 2007, 8:844-858.
38. Kebabian J.W., Britton D.R., De Ninno M.P., Perner R., Smith L., Jenner P., et al. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. European Journal of Pharmacology 1992, 229:203-209.
39. Khroyan T.V., Fuchs R.A., Baker D.A., Neisewander J.L. Effects of D3-preferring agonists 7-OH-PIPAT and PARKINSON'S DISEASE-128,907 on motor behaviors and place conditioning. Behavioural Pharmacology 1997, 8:65-74.
40. Kivastik T., Vuorikallas K., Piepponen T.P., Zharkovsky A., Ahtee L. Morphine- and cocaine-induced conditioned place preference: effects of quinpirole and preclamol. Pharmacology Biochemistry and Behavior 1996, 54:371-375.
41. Kling-Petersen T., Ljung E., Wollter L., Svensson K. Effects of dopamine D3 preferring compounds on conditioned place preference and intracranial self-stimulation in the rat. Journal of Neural Transmission General Section 1995, 101:27-39.
42. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
43. Le Foll B., Frances H., Diaz J., Schwartz J.C., Sokoloff P. Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. European Journal of Neuroscience 2002, 15:2016-2026.
44. Le Foll B., Schwartz J.C., Sokoloff P. Disruption of nicotine conditioning by dopamine D3 receptor ligands. Molecular Psychiatry 2003, 8:225-230.
45. Foll Le., Diaz B.J., Sokoloff P. Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse 2003, 47:176-183.
46. Le.Foll B., Goldberg S.R., Sokoloff P. The dopamine D3 receptor and drug dependence: effects on reward or beyond?. Neuropharmacology 2005, 49:525-541.
47. Le Foll B., Gallo A., Le Strat Y., Lu L., Gorwood P. Genetics of dopamine receptors and drug addiction: a comprehensive review. Behavioural Pharmacology 2009, 20:1-17.
48. Lévesque D., Martres M.P., Diaz J., Griffon N., Lammers A. paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:1719-1723.
49. Limotai N., Oyama G., Go C., Bernal O., Ong T., Moum S.J., et al. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience. International Journal of Neuroscience 2012, 122:145-153.
50. Lin C.W., Bianchi B.R., Miller T.R., Stashko M.A., Wang S.S., Curzon P., et al. Persistent activation of the dopamine D1 receptor contributes to prolonged receptor desensitization: studies with A-77636. Journal of Pharmacology and Experimental Therapeutics 1996, 276:1022-1029.
51. Margolis E.B., Mitchell J.M., Ishikawa J., Hjelmstad G.O., Fields H.L. Midbrain dopamine neurons: projection target determines action potential duration and dopamine D(2) receptor inhibition. Journal of Neuroscience 2008, 28:8908-8913.
52. Mash D.C., Staley J.K. D3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims. Annals of the New York Academy of Sciences 1999, 877:507-522.
53. Meyers J., Candrilli S., Allen R., Manjunath R., Calloway M. Health care resource utilization and costs associated with restless legs syndrome among managed care enrollees treated with dopamine agonists. Managed Care 2012, 21:44-51.
54. Narita M., Mizuo K., Mizoguchi H., Sakata M., Narita M., Tseng L.F., et al. Molecular evidence for the functional role of dopamine D3 receptor in the morphine-induced rewarding effect and hyperlocomotion. Journal of Neuroscience 2003, 23:1006-1012.
55. Nestler E.J. Is there a common molecular pathway for addiction?. Nature Neuroscience 2005, 8:1445-1449.
56. O'Sullivan S.S., Evans A.H., Lees A.J. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009, 23:157-170.
57. Pioli E.Y., Meissner W., Sohr R., Gross C.E., Bezard E., Bioulac B.H. Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats. Neuroscience 2008, 153:1213-1224.
58. Pizzagalli D.A., Evins A.E., Schetter E.C., Frank M.J., Pajtas P.E., Santesso D.L., et al. Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. Psychopharmacology (Berl) 2008, 196:221-232.
59. Prieto G.A., Perez-Burgos A., Palomero-Rivero M., Galarraga E., Drucker-Colin R., Bargas J. Upregulation of D2-class signaling in dopamine-denervated striatum is in part mediated by D3 receptors acting on Ca V 2.1 channels via PIP2 depletion. Journal of Neurophysiology 2011, 105:2260-2274.
60. Riddle J.L., Rokosik S.L., Napier T.C. Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls. Behavioural Brain Research 2012, 233:15-23.
61. Rinne U.K., Laihinen A., Rinne J.O., Någren K., Bergman J., Ruotsalainen U. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Movement Disorders 1990, 5:55-59.
62. Roberts D.C., Koob G.F., Klonoff P., Fibiger H.C. Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacology Biochemistry and Behavior 1980, 12:781-787.
63. Roberts D.C., Koob G.F. Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. Pharmacology Biochemistry and Behavior 1982, 17:901-904.
64. Roberts D.C., Morgan D., Liu Y. How to make a rat addicted to cocaine. Progress in Neuropsychopharmacology & Biological Psychiatry 2007, 31:1614-1624.
65. Robinson T.E., Kolb B. Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology 2004, 47(Suppl. 1):33L 46.
66. Rodríguez De Fonseca F., Rubio P., Martín-Calderón J.L., Caine S.B., Koob G.F., Navarro M. The dopamine receptor agonist 7-OH-DPAT modulates the acquisition and expression of morphine-induced place preference. European Journal of Pharmacology 1995, 274:47-55.
67. Rogers D.C., Martel F.L., Dunnelt S.B. Nigral grafts in neonatal rats protect from aphagia induced by subsequent adult 6-OHDA lesions: the importance of striatal location. Experimental Brain Research 1990, 80:172-176.
68. Samii A., Nutt J.G., Ransom B.R. Parkinson's disease. Lancet 2004, 363:1783-1793.
69. Sautel F., Griffon N., Lévesque D., Pilon C., Schwartz J.C., Sokoloff P. A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport 1995, 6:329-332.
70. Savasta M., Mennicken F., Chritin M., Abrous D.N., Feuerstein C., Le Moal M., et al. Intrastriatal dopamine-rich implants reverse the changes in dopamine D2 receptor densities caused by 6-hydroxydopamine lesion of the nigrostriatal pathway in rats an autoradiographic study. Neuroscience 1992, 46:729-738.
71. Savasta M., Dubois A., Benavidès J., Scatton B. Different plasticity changes in D1 and D2 receptors in rat striatal subregions following impairment of dopaminergic transmission. Neuroscience Letters 1988, 85:119-124.
72. Schwarz S.S., Freed W.J. Brain tissue transplantation in neonatal rats prevents a lesion-induced syndrome of adipsia, aphagia and akinesia. Experimental Brain Research 1987, 65:449-454.
73. Seedat S., Kesler S., Niehaus D.J., Stein D.J. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 2000, 11:185-186.
74. Seeman P., Ko F., Willeit M., McCormick P., Ginovart N. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors. Synapse 2005, 58:122-128.
75. Segal D.M., Moraes C.T., Mash D.C. Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Research Molecular Brain Research 1997, 45:335-339.
76. Staley J.K., Mash D.C. Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. Journal of Neuroscience 1996, 16:6100-6106.
77. Tzschentke T.M. Measuring reward with the conditioned place preference (CPP) paradigm: Parkinson's disease ate of the last decade. Addiction Biology 2007, 12:227-462.
78. Voon V., Mehta A.R., Hallett M. Impulse control disorders in Parkinson's disease: recent advances. Current Opinion in Neurology 2011, 24:324-330.
79. Vorel S.R., Ashby C.R., Paul M., Liu X., Hayes R., Hagan J.J., et al. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. Journal of Neuroscience 2002, 22:9595-9603.
80. Weintraub D., Koester J., Potenza M.N., Siderowf A.D., Stacy M., Voon V., et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Archives of Neurology 2010, 67:589-595.
81. White N.M., Packard M.G., Hiroi N. Place conditioning with dopamine D1 and D2 agonists injected peripherally or into nucleus accumbens. Psychopharmacology (Berl) 1991, 103:271-276.
82. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychology Review 1987, 94:469-492.
83. Wise R.A. Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotoxicology Research 2008, 14:169-183.
84. Wolf M.E. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Progress in Neurobiology 1998, 54:679-720.
85. Zengin-Toktas Y., Authier N., Denizot H., Chassain C., Hafidi A., Llorca P.M., et al. Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and l-dopa, in bilateral 6-OHDA-lesioned rat. Neuropharmacology 2013, 70C:74-82.